Fate Therapeutics, Inc. (NASDAQ:FATE) Reported Basic Consolidated EPS Of $-1.1769 For Period Ended 2015-12-31

0

The annual basic consolidated EPS for Fate Therapeutics, Inc. (NASDAQ:FATE) for the period ended 2015-12-31 was $-1.1769. On quarterly basis, the basic consolidated EPS reading for the quarter ended 2015-12-31 was $-1.1769.

EPS from continuing operations

Coming to basic EPS from continuing operations, Fate Therapeutics, Inc. (NASDAQ:FATE) reported $-1.1769 for the annual period ended 2015-12-31. Quarterly basic EPS from continuing operations for the three-month period ended 2015-12-31 stood at $-1.1769.

EPS contribution from parent

For the annual period ended 2015-12-31, Fate Therapeutics, Inc. (NASDAQ:FATE) received basic EPS of $-1.1769 from its parent company. On quarterly basis, basic EPS contribution from the parent company for the period ended 2015-12-31 was $-1.1769.

Basic net EPS

For the annual period ended 2015-12-31, Fate Therapeutics, Inc. (NASDAQ:FATE) reported basic net EPS of $-1.18. On quarterly basis, the company’s basic net EPS for the three-month period ended 2015-12-31 stood at $-1.18.

Consolidated diluted EPS

The annual consolidated diluted EPS reading for the period ended 2015-12-31 stood at $-1.1769. For the quarter ended 2015-12-31, consolidated diluted EPS was $-1.1769.

Basic diluted EPS

On annual basis, diluted EPS reading from continuing operation was $-1.1769 for the period ended 2015-12-31. Diluted EPS from continuing operations for the quarter ended 2015-12-31 was $-1.1769.

Net diluted EPS

Net diluted EPS reading for the annual period ended 2015-12-31 was $-1.18. For the quarterly period ended 2015-12-31, net diluted EPS was $-1.18.

Diluted EPS from parent

From the parent company, Fate Therapeutics, Inc. (NASDAQ:FATE) received diluted EPS of $-1.1769 for the annual period ended 2015-12-31. On quarterly basis, diluted EPS contribution from the parent for the quarter ended 2015-12-31 was $-1.1769.

Fate Therapeutics, Inc. (NASDAQ:FATE) posted net basic EPS reading of $-1.18 for the annual period ended 2015-12-31. For the quarter, basic net EPS of $-1.18 was for the quarter ended 2015-12-31.

Net diluted EPS for Fate Therapeutics, Inc. (NASDAQ:FATE) for the annual period ended 2015-12-31 was $-1.18. The company also reported net diluted EPS reading of $-1.18 for the quarter ended 2015-12-31.

The annual average basic shares outstanding for the period ended 2015-12-31 is 25.484 while for the quarter ended 2015-12-31 is 25.484.

The diluted shares outstanding for the fiscal year ended is 2015-12-31 is 25.484 while for the quarter ended 2015-12-31 is 25.484.

1 Chart Pattern Every Investor Should Know

This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...

Click Here to See This Now.

(Visited 18 times, 1 visits today)